Figure 4.

L-arginine/NO pathway metabolites as biomarkers in CRC surveillance in IBD patients: (a) Arginine; (b) citrulline; (c) asymmetric dimethylarginine—ADMA; (d) symmetric dimethylarginine—SDMA; (e) dimethylamine—DMA; (f) metabolite panel consisting of SDMA and ADMA. Data presented as receiver operating characteristic (ROC) curves with a 95% confidence interval (CI) and as an area under the ROC curve (AUC) with a 95% (CI) and significance of difference from AUC = 0.5, characteristic for a chance marker (represented as diagonal line). The red dot indicates Youden index.